Earnings Call Insights: Hinge Health (HNGE) Q4 2025 Management View Daniel Perez, Co-Founder, CEO & Director, described 2025 as "an exceptional year that demonstrated the power of our vision to automate health care delivery through technology." He highlighted that Hinge Health delivered $171 million in Q4 revenue, up 46% year-over-year, and $588 million for the full year, reflecting 51% growth com...
Earnings Call Insights: Hinge Health (HNGE) Q4 2025 Management View Daniel Perez, Co-Founder, CEO & Director, described 2025 as "an exceptional year that demonstrated the power of our vision to automate health care delivery through technology." He highlighted that Hinge Health delivered $171 million in Q4 revenue, up 46% year-over-year, and $588 million for the full year, reflecting 51% growth compared to 2024. The company ended 2025 with nearly 25 million contracted lives and over 2,800 clients, spanning multiple industries. Perez emphasized advancements in AI-powered tools, noting that "in 2025, we served 47% more members while keeping care team costs flat." The rollout of the AI care assistant Robin, which received a 92% positive member rating, contributed to a 28% reduction in care team time per asynchronous session from Q3 to Q4. He also stated, "our member NPS scores are at an all-time high." HingeSelect, the company's high-performance provider network, gained traction, with Perez noting that "about 85% of HingeSelect members were able to move forward with a conservative care plan, most often digital physical therapy." President James Pursley reported the addition of 4.8 million net new contracted lives in 2025, bringing the total to approximately 24.6 million. He pointed out, "our clients now represent 53% of the Fortune 100 and 45% of the Fortune 500," highlighting the company's penetration among large enterprises. CFO James Budge stated, "Q4 revenue came in at $171 million, up 46% year-over-year from $117 million in the prior year fourth quarter and well ahead of our guidance range of $155 million to $157 million." Budge noted strong yield improvements, with net dollar retention well above 110%. He also highlighted, "we generated $62 million in free cash flow in Q4, representing a free cash flow margin of 36%." Budge reported a diluted net income per share in Q4 of $0.49. Outlook CFO Budge provided guidance for 2026, stating, "For the first quarter of 2026,...
Even with a big sell-off today, Jumia stock is still up 159% over the last year. Jumia (JMIA 15.81%) stock took a hit on Tuesday. The African e-commerce company's share price fell 15.8% in a day of trading that saw the S&P 500 decline 0.4% and the Nasdaq Composite sink 0.6%. Jumia published its fourth-quarter results before the market opened this morning and reported sales that came in ahead of Wa...
Even with a big sell-off today, Jumia stock is still up 159% over the last year. Jumia (JMIA 15.81%) stock took a hit on Tuesday. The African e-commerce company's share price fell 15.8% in a day of trading that saw the S&P 500 decline 0.4% and the Nasdaq Composite sink 0.6%. Jumia published its fourth-quarter results before the market opened this morning and reported sales that came in ahead of Wall Street's expectations. On the other hand, the business posted a wider-than-anticipated loss. Jumia misses Q4 earnings expectations Jumia managed to grow revenue 34.4% year over year to hit $61.4 million in the fourth quarter, beating the average analyst estimate of approximately $60.66 million. Despite the sales beat, Jumia's loss for the quarter came in higher than anticipated. The business posted a loss of $0.08 per share in the period, exceeding the average analyst estimate's call for a per-share loss of $0.05. Expand NYSE : JMIA Jumia Technologies Ag Today's Change ( -15.81 %) $ -1.94 Current Price $ 10.33 Key Data Points Market Cap $1.5B Day's Range $ 10.06 - $ 10.91 52wk Range $ 1.60 - $ 14.72 Volume 9.3M Avg Vol 3.2M Gross Margin 48.15 % What's next for Jumia? Even with today's valuation pullback, Jumia stock is still up approximately 159% over the last year. The company now has a market capitalization of approximately $1.27 billion and is valued at approximately 5.2 times this year's expected sales. k Given Jumia's recent sales growth rate, the company could appear undervalued on a price-to-sales basis. On the other hand, the company has an uneven growth history -- and concerns remain about the business's ability to shift into delivering reliable profits.
Key Points Jumia posted strong sales growth in Q4, but the business notched a wider-than-expected loss. Jumia stock is still up big over the last year, but investors may need to see improvements on the margin front going forward. 10 stocks we like better than Jumia Technologies Ag › Jumia (NYSE: JMIA) stock took a hit on Tuesday. The African e-commerce company's share price fell 15.8% in a day of ...
Key Points Jumia posted strong sales growth in Q4, but the business notched a wider-than-expected loss. Jumia stock is still up big over the last year, but investors may need to see improvements on the margin front going forward. 10 stocks we like better than Jumia Technologies Ag › Jumia (NYSE: JMIA) stock took a hit on Tuesday. The African e-commerce company's share price fell 15.8% in a day of trading that saw the S&P 500 decline 0.4% and the Nasdaq Composite sink 0.6%. Jumia published its fourth-quarter results before the market opened this morning and reported sales that came in ahead of Wall Street's expectations. On the other hand, the business posted a wider-than-anticipated loss. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Jumia misses Q4 earnings expectations Jumia managed to grow revenue 34.4% year over year to hit $61.4 million in the fourth quarter, beating the average analyst estimate of approximately $60.66 million. Despite the sales beat, Jumia's loss for the quarter came in higher than anticipated. The business posted a loss of $0.08 per share in the period, exceeding the average analyst estimate's call for a per-share loss of $0.05. What's next for Jumia? Even with today's valuation pullback, Jumia stock is still up approximately 159% over the last year. The company now has a market capitalization of approximately $1.27 billion and is valued at approximately 5.2 times this year's expected sales. k Given Jumia's recent sales growth rate, the company could appear undervalued on a price-to-sales basis. On the other hand, the company has an uneven growth history -- and concerns remain about the business's ability to shift into delivering reliable profits. Should you buy stock in Jumia Technologies Ag right now? Before you buy stock in Jumia Technologies Ag, consider this: The Mot...
Earnings Call Insights: Exelixis, Inc. (EXEL) Q4 2025 Management View CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all components of our business,” reaffirming a “singular focus to build a multi-franchise business in solid tumor oncology based on the foundation of cabozantinib, the potential of zanzalintinib and the depth of our early-stage pipeline....
Earnings Call Insights: Exelixis, Inc. (EXEL) Q4 2025 Management View CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all components of our business,” reaffirming a “singular focus to build a multi-franchise business in solid tumor oncology based on the foundation of cabozantinib, the potential of zanzalintinib and the depth of our early-stage pipeline.” He highlighted “continued strong performance of the cabozantinib business,” with CABOMETYX maintaining its position as “the leading TKI for RCC and the market leader for neuroendocrine tumors in the oral second-line plus segment.” Morrissey emphasized the company’s “franchise-focused approach,” noting the strategy to “expand our leadership in GI indications with equal intensity and potential upside.” He revealed that “cabo's U.S. net product revenues exceeded $100 million for the neuroendocrine tumor indication in 2025.” Morrissey announced the NDA acceptance for the zanzalintinib/atezolizumab combination in third-line plus CRC and the build-out of the GI sales team to “accelerate the growth of the CABOMETYX neuroendocrine tumor opportunity before zanza could come online for CRC later in the year.” CFO Christopher Senner reported, “For the fourth quarter of 2025, the company reported total revenues of approximately $599 million, which included cabozantinib franchise net product revenues of $546.6 million.” Senner added, “Gross to net for the cabozantinib franchise in the fourth quarter of 2025 was 28.5%, which is lower than the gross to net we experienced in the third quarter of 2025.” He also noted, “The company reported GAAP net income of approximately $244.5 million or $0.92 per share basic and $0.88 per share diluted for the fourth quarter of 2025.” Executive Vice President of Commercial P.J. Haley stated, “The CABOMETYX business remained strong in the fourth quarter of 2025,” and highlighted “CABOMETYX TRx volume grew 15% in Q4 2025 compared to Q4 2024, outpacing the...
Musk Offers Legal Fees For Anyone Sued Who 'Speaks The Truth' About Epstein Authored by Rachel Roberts via The Epoch Times (emphasis ours), Tech billionaire Elon Musk said he will pay the legal fees of anyone who speaks out about alleged perpetrators whose names have been redacted from the Jeffrey Epstein files and is sued as a result. Elon Musk attends a dinner hosted by President Donald Trump at...
Musk Offers Legal Fees For Anyone Sued Who 'Speaks The Truth' About Epstein Authored by Rachel Roberts via The Epoch Times (emphasis ours), Tech billionaire Elon Musk said he will pay the legal fees of anyone who speaks out about alleged perpetrators whose names have been redacted from the Jeffrey Epstein files and is sued as a result. Elon Musk attends a dinner hosted by President Donald Trump at the White House in Washington, on Nov. 18, 2025. REUTERS/Tom Brenner The Tesla CEO made the offer in response to a public service announcement played on Super Bowl Sunday that featured women alleging abuse by Epstein and his associates. The 40-second video clip notes that 3 million files related to the late sex offender have not yet been released . The women are depicted holding photographs of their younger selves, with black boxes to symbolize redactions over their mouths. The accusers then reiterate their commitment to standing together to demand the full truth about Epstein’s criminal network. They then urge Attorney General Pam Bondi, “It’s time for the truth.” Daily Wire commentator Matt Walsh questioned on Musk’s platform, X, why the women had not publicly named their alleged abusers, and suggested they could do so safely through congressional advocates. Walsh wrote on Sunday, “For those claiming that they can’t name names because they’ll be sued: they could simply give the names to any of their many (and mostly very recent) advocates in congress, who could read the names out loud from the floor, insulating themselves and these women from any litigation. But they refuse to do that. Why?” Redactions Musk posted in response to Walsh: “I will pay for the defense of anyone who speaks the truth about this and is sued for doing so.” The offer could potentially give financial protection to victims who fear legal retaliation for naming individuals linked to Epstein, who died in custody in 2019 while awaiting trial on multiple charges of trafficking minors. His death was rule...
A man who posed as a teenager online to talk to underage girls was sentenced to 11 years’ jail and 10 strokes of the cane on Tuesday. The Singaporean, now aged 25, who cannot be named due to gag orders protecting the identity of two victims, pleaded guilty to two counts of statutory rape, one count of sexual grooming of a minor and one count of sexual penetration of a minor. Another 14 charges wer...
A man who posed as a teenager online to talk to underage girls was sentenced to 11 years’ jail and 10 strokes of the cane on Tuesday. The Singaporean, now aged 25, who cannot be named due to gag orders protecting the identity of two victims, pleaded guilty to two counts of statutory rape, one count of sexual grooming of a minor and one count of sexual penetration of a minor. Another 14 charges were taken into consideration for sentencing. Advertisement The court heard that the offender held various jobs such as a banquet server, warehouse assistant, swimming teacher, clerk and luge operator. In August 2023, when the offender was 22 years old, he matched with a 13-year-old girl on a Telegram bot. Advertisement The offender knew the girl’s age, as she stated it in her profile. Although the offender lied in his profile that he was 15, the girl asked him about his age as he looked older in his photos.
Chinese consumers are experiencing "luxury shame" similar to what happened in the U.S. during the 2008-09 financial crisis, according to a June Bain and Company report. Jade Gao | Afp | Getty Images China's consumer inflation rose less than expected in January while the deflation in producer prices persisted, in a sign of continued deflationary pressure in the absence of stronger stimulus. The con...
Chinese consumers are experiencing "luxury shame" similar to what happened in the U.S. during the 2008-09 financial crisis, according to a June Bain and Company report. Jade Gao | Afp | Getty Images China's consumer inflation rose less than expected in January while the deflation in producer prices persisted, in a sign of continued deflationary pressure in the absence of stronger stimulus. The consumer price index rose 0.2% in January from a year earlier, China's National Bureau of Statistics data showed on Wednesday, below economists' forecast of 0.4% increase in a Reuters poll. That followed a 0.8% growth in December , its highest level in nearly three years. Prices rose 0.2% month-on-month, below economists' forecast of a 0.3% increase. Core CPI, which strips out volatile food and energy prices, jumped 0.8% from a year earlier, easing from the 1.2% in December. China's producer price index declined 1.4% from a year ago, better than economists' expectations of a 1.5% drop, official data showed, moderating from a 1.9% drop in December . The deflation in factory-gate prices has persisted for more than three years, weighing on the profitability of manufacturers who have weathered tepid consumer confidence and production disruptions stemming from U.S. trade policies for much of last year. The world's second-largest economy grew 5% last year, in line with Beijing's official target, thanks to resilient export growth to non-U.S. markets. China has struggled to shake deflationary pressure since the end of the pandemic, weighed down by a prolonged property downturn and uncertain job-market prospects. Authorities have sought to curb price wars across industries, where overcapacity has fueled a glut of goods and forced companies to cut prices. Top policymakers are expected to unveil economic targets for the year at a parliamentary meeting next month. In a policy report on Tuesday, the People's Bank of China reiterated its determination to implement "appropriately loose" mone...
Hong Kong stocks rose on Wednesday, supported by holiday-related flows ahead of the Lunar New Year break, with investors adjusting positions as the market heads into a shortened trading schedule next week. The Hang Seng Index rose 0.2 per cent to 27,246.18 at the open, adding to the 0.6 per cent gain recorded on Tuesday. The Hang Seng Tech Index climbed 0.2 per cent. On the mainland, the CSI 300 I...
Hong Kong stocks rose on Wednesday, supported by holiday-related flows ahead of the Lunar New Year break, with investors adjusting positions as the market heads into a shortened trading schedule next week. The Hang Seng Index rose 0.2 per cent to 27,246.18 at the open, adding to the 0.6 per cent gain recorded on Tuesday. The Hang Seng Tech Index climbed 0.2 per cent. On the mainland, the CSI 300 Index and the Shanghai Composite Index were little changed. Wuxi Biologics jumped 3.6 per cent to HK$41.44 after reporting a nearly 22 per cent rise in net profit, beating market expectations. Techtronic Industries rose 1.8 per cent to HK$116.40, and Innovent Biologics surged 1.4 per cent to HK$90.90. Short-video sharing platform Kuaishou Technology added 1.4 per cent to HK$71.35, and blind-box toymaker Pop Mart International advanced 1.3 per cent to HK$273.20. Advertisement Chinese chipmaker SMIC lost 2.4 per cent to HK$69.85 after fourth quarter net income missed estimates. WeChat operator Tencent Holdings slid 1.5 per cent to HK$543, and online travel-booking agency Trip.com declined 1.5 per cent to HK$442. Hong Kong stocks will trade for only half a day on Monday before closing for the holiday, reinforcing near-term calendar effects on market moves. The benchmark typically sees lighter volumes and a positive bias ahead of the holiday, as traders square positions and selectively add exposure before the break. Advertisement Two stocks debuted on Wednesday. Wuxi Lead Intelligent Equipment added 1 per cent to HK$46.26 in Hong Kong, and Isvision (Hangzhou) Technology advanced 8 per cent to 100 yuan in Shanghai.
US singer Britney Spears has become the latest musician to sell the rights to her catalogue that includes hits like “Baby One More Time” and “Oops!...I Did It Again”, US media reported on Tuesday. The deal is believed to be worth around US$200 million, according to sources cited by celebrity site TMZ, though it said the exact amount is not detailed in legal documents. That sum would be comparable ...
US singer Britney Spears has become the latest musician to sell the rights to her catalogue that includes hits like “Baby One More Time” and “Oops!...I Did It Again”, US media reported on Tuesday. The deal is believed to be worth around US$200 million, according to sources cited by celebrity site TMZ, though it said the exact amount is not detailed in legal documents. That sum would be comparable to the sale of Canadian singer Justin Bieber’s catalogue in 2023. Advertisement Spears, 44, joins a growing list of artists who have sold their music rights in recent years. Notable sellers include Bruce Springsteen, who in 2021 made a deal with Sony Music Entertainment to relinquish his master recordings and songs for US$500 million. Shortly thereafter, David Bowie’s estate sold his songwriting catalogue to Warner Chappell Music for US$250 million. ZZ Top, Tina Turner and Paul Simon all made similar deals around the same time. Advertisement The Hollywood Reporter reported that the rights to Spears’ music were bought by music publisher Primary Wave, whose portfolio includes the works of Whitney Houston, Bob Marley, Prince and others.
Elon Musk announced his new company xAI which he says has the goal to understand the true nature of the universe. Jaap Arriens | Nurphoto | Getty Images Elon Musk's xAI has lost its second co-founder in two days. Influential researcher Jimmy Ba on Tuesday announced his departure in a post on X, thanking Musk and writing that he was, "Grateful to have helped cofound at the start." Ba's departure co...
Elon Musk announced his new company xAI which he says has the goal to understand the true nature of the universe. Jaap Arriens | Nurphoto | Getty Images Elon Musk's xAI has lost its second co-founder in two days. Influential researcher Jimmy Ba on Tuesday announced his departure in a post on X, thanking Musk and writing that he was, "Grateful to have helped cofound at the start." Ba's departure comes just one day after fellow co-founder Tony Wu announced his own exit from xAI, which merged with Musk's aerospace company SpaceX earlier this month. The xAI co-founder exodus comes as SpaceX prepares to go public sometime this year. A University of Toronto professor, Ba was credited for critical research that influenced the company's Grok version 4 AI models. Besides Ba and Wu, other co-founders including Igor Babuschkin , Kyle Kosic and Christian Szegedy, have also departed Musk's artificial intelligence venture. Greg Yang announced last month that he would be stepping back from his role to focus on his battle with Lyme disease. The record-setting, all-stock deal valued SpaceX at $1 trillion and xAI at $250 billion, according to documents viewed by CNBC. Musk previously used xAI to acquire his social network X, formerly Twitter, in another all-stock transaction announced in March 2025 . The departures also come as xAI faces regulatory probes in multiple jurisdictions across Europe, Asia and the U.S. The probes were initiated after the company's Grok AI chatbot and image generator allowed mass-creation and syndication of non-consensual, explicit images, colloquially known as deepfake porn. The images were based on photos of real people, including children. Musk launched xAI in 2023 alongside 11 other people in an effort to compete against OpenAI and Google . The company's stated goal was to "understand the true nature of the universe," according to its website at the time. The company did not immediately respond to a request for comment. WATCH: SpaceX deal to aquire xAI ...